Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Scinai Immunotherapeutics Ltd.

$0.4

-0.02 (-4.16%)

Market Cap
1.60 M
EPS
-10.26
P/E Ratio
-
Value Trade
83.74 K
SEC Financials
Q1 2023
  • Dilution Risk

    95%
  • R&D Expenses

    2.00 M

  • Operating CF

    -3.06 M


  • Total Assets

    23.29 M

  • Total Liabilities

    23.29 M

  • Equity

    -4.81 M

  • D/E Ratio

    12,345

-9.57 %
Week
-17.94 %
1 Month
-42.08 %
3 Month
-49.32 %
6 Month
-99.84 %
5 Year
-99.91 %
All Time
Cash Data
Critical
  • Cash Position

    10.80 M

  • Monthly Burn

    1.02 M

  • Runway

    0 mo

  • Burn Trend

    Accelerating
  • SEC Filing

    May 15, 2023
Overview
Volume
82.38 K
52 Week Range
0.44 - 6.18
% held by Insiders
2.25 %
% held by Institutions
0.78 %
Enterprise Value
7.68 M
Total Shares
3.47 M
Short %
4.66 %
Float Shares
3.39 M
Company Description
HQ: JERUSALEM BIOPARK, 2ND FLOOR, ...
Employees:45

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
Unlock Drug Pipeline Intelligence
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLD
INSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLD
HEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in SCNI
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SCNI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SCNI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SCNI
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
SCNI Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
SCNI Institutional Ownership Trends
Current Insider %
5.20%
+0.00%
Current Institutional %
62.40%
+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Scinai Immunotherapeutics Ltd. (SCNI) News & Alerts
-
Monday, June 8, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How SCNI ranks across every disease it competes in
No competitive intelligence available for SCNI.